|
Post by JHam on Mar 31, 2015 14:24:02 GMT
I tweeted to JP and nobody knows what's up - not usually a good sign. Nothing for sure yet. Might be another hour or so. Jason Napodano, CFA @jnapodano 2m2 minutes ago Participants in $CYNAF financing include >> Orbimed, Dafna, Venrock, Sphera, Broadfin, Dexon… Great names!! No warrants. $CTH.T
|
|
|
Post by Yelk on Mar 31, 2015 14:30:34 GMT
Well, not a buyout but not bad news - that is good.
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease, today announced the completion of a private placement (the “Offering”) of 22,039,472 common shares of the Company (the “Common Shares”) for gross proceeds of CAD$20,981,579. The financing was led by funds associated with OrbiMed, Aisling Capital and Venrock, with participation from various other institutional investors, including existing shareholders Broadfin Capital, Sphera Funds Management, Pura Vida Investments, DAFNA Capital Management and Dexcel Pharma Technologies Ltd./Dexxon Holdings Ltd (“Dexcel”). “We greatly appreciate the confidence shown by such high-quality life science investors in leading this financing,” commented Anthony Giovinazzo, Cynapsus' President and Chief Executive Officer. “This fund raise provides us with further resources to undertake our Phase 3 clinical studies in the United States, file an expected New Drug Application in 2016, and continue with our strategic objectives.”
|
|
|
Post by Yelk on Mar 31, 2015 15:08:42 GMT
Market is reacting quite good. I was expecting a big dip TBH. While it still could go red on the day I think this was good to get out of the system. This will pave the path moving forward.
|
|
|
Post by Yelk on Apr 6, 2015 23:36:08 GMT
Stock has been ramping up nicely and broke some higher closers. Will take some time but I expect major upside here before P3 results
|
|
|
Post by Yelk on Apr 9, 2015 3:20:00 GMT
CYNAF down 22% aftermarket hours. Only 60K volume and looks like a block sell. I really hope that was an accidental sell or something and triggered some very low buys.... will see tomorrow still makes me nervous. Very odd.
|
|
|
Post by forthefuture on Apr 9, 2015 5:43:29 GMT
Definitely odd, but nothing I can think of fundamentally that would trigger a sell so low.
|
|
|
Post by Yelk on Apr 9, 2015 12:50:30 GMT
Definitely odd, but nothing I can think of fundamentally that would trigger a sell so low. It was a cancelled trade that had to be out in, don't worry about it!
|
|
|
Post by Yelk on Apr 21, 2015 21:53:19 GMT
Stock is so undervalued its crazy. Just FYI company is voting for reverse split with shareholders and up list. I think it would be good.
I don't know how much lower it can go here with this tiny market cap...
|
|
|
Post by Yelk on May 11, 2015 1:54:27 GMT
Update: The company will be uplisting to Nasdaq, financing is not a big risk for now, the 6 week trial for efficacy is underway and bridge study about to start any day. The stock has been dipping like crazy and I'm trying to remain strong for the potential breakout.
|
|
|
Post by Yelk on May 16, 2015 16:42:16 GMT
I'd highly recommend reading this full aticle by JN will take a few min bionapcfa.blogspot.ca/2015/03/cynapsus-readies-for-pivotal-program.htmlThere is a good chance the company will be bought out at over 5x its current value and even if not Why read? The P3 study if demonstrates similar efficacy as P2 will result in 5-8x upside within the next few years without a buyout, with a buyout possibly within the next year anytime. Why do I think p3 has 75% chance of success or more? Phase 2(completed):Fifteen of the 19 patients (~79%) turned “on” after dosing APL-130277. Of the four patients that did not turn “on”, two were dosed incorrectly (told to swallow the film strip instead of letting it dissolve) and two were believed to require doses higher than 30 mg because their baseline UPDRS scores were significantly higher than the mean for the other 17 patients. This is consistent with prescribing label for subcutaneous apomorphine were approximately 20% of PD patients require the highest dose. Nevertheless, all five doses of APL-130277 used in the study (10, 15, 20, 25, 30 mg) did result in patients moving from “off” to “on”. We are encouraged by the fact that even the lowest dose showed efficacy, with 3 of the 19 patients (~16%) moving to “on”. Another nine patients turned “on” when doses were increased to 20 mg. All patients that turned “on” did so in 30 minutes or less, with half turning “on” after only 15 minutes. Mean time to "full on” was 22 minutes. Phase 3(underway):The primary efficacy trial for the Phase 3 program, CTH-300, will be a double-blind, placebo-controlled, parallel-design study with an estimated 126 PD patients who have at least one “off” episode every 24 hours, with total “off” time of at least two hours per day (1:1 randomization). The objective is to evaluate the efficacy and safety of APL-130277 versus placebo in patients with PD over a 12 week period. The primary end point will be the mean change in the Unified Parkinson’s Disease Rating Scale Part III (UPDRS III) score at 30 minutes after dosing. Enrollment will take place at roughly 35 centers through North America, with a target start date of June 2015. Top-line data is expected around March 2016. Since APL-130277 is being compared to placebo, we view this trial as having a very high probability of success. Additionally the drug is VERY easy to use, simply put under the tongue, no painful injections or hard to approve chronic inhalation like competition. It is also affordable, safe for repetitive use, on time is faster than others AND lasts longer. Finally the company just completed financing and is good through 2017 which is after NDA filing or buyout. As I mentioned earlier the company will be uplisting to Nasdaq and has hired BOAML to promote. Currently the share price is on a nice dip which represents an opportunity to start in before any of future/safety studies start or complete in the next few weeks. Please do your own due diligence but I wanted to bring this to everyone's attention and though most of this has been discussed here I believe this company has been overlooked. The risk/reward is as good as even Athersys projected PPS for a 1 year period and the risk if FAR less with clear cut science and data. Edit of importance: The company will be raising 60mill another U.S. offering done by BOAML for IPO is U.S. a company similar for Parkinsons did the same in 2014 and got purchased by Acorda for $525 million and cynpasus has a better drug. We may see a share drop here next week, not sure - but things are about to get interesting through June.http://www.nasdaq.com/article/parkinsons-biotech-cynapsus-therapeutics-files-for-a-60-million-us-ipo-cm477487
|
|
|
Post by Yelk on May 18, 2015 16:26:06 GMT
Canadian markets not open today but strong buying U.S. Up over 7% so far. Was a bit surprised considering financing but could be people realize a buyout is possible soon.
|
|
|
Post by Yelk on Jun 10, 2015 4:19:42 GMT
Very excited about the trial data coming and possible NDA submission if we are good to go. This is a stock to watch for the next year. 60% size at the moment. As a reminder the target start date is June and the company is doing its own financing (gives more value to shareholders if there is a buyout for negotiation or more value if self generation of future revenue). I am a fairly large position in case there is a buyout but leaving room for any large pullbacks before the early 2016 runup.
Now that the reverse stock split is done and all financing news is done and public I am optimistic we will see little further pullback and we can begin a slow curl back to 52 week highs by end of 2015.
|
|
|
Post by JHam on Jun 18, 2015 1:04:04 GMT
I know nothing about this company, but $63M raised, 4.5M shares at $14 with no warrants. Plus they up-list to the Nasdaq tomorrow. Gotta like that. Good luck!
|
|
|
Post by Yelk on Jun 18, 2015 4:22:44 GMT
I know nothing about this company, but $63M raised, 4.5M shares at $14 with no warrants. Plus they up-list to the Nasdaq tomorrow. Gotta like that. Good luck! I'd highly recommend taking a look. JN has some good articles on it for starters.
|
|
|
Post by JHam on Jun 18, 2015 6:55:22 GMT
I know nothing about this company, but $63M raised, 4.5M shares at $14 with no warrants. Plus they up-list to the Nasdaq tomorrow. Gotta like that. Good luck! I'd highly recommend taking a look. JN has some good articles on it for starters. Yeah I have seen them. I have not been too impressed with JN lately. He is kind of all over the place lately and got caught BSing this one on Twitter. If there is a big dump due to this offering I will take a look.
|
|
|
Post by Yelk on Jun 19, 2015 4:16:03 GMT
I'd highly recommend taking a look. JN has some good articles on it for starters. Yeah I have seen them. I have not been too impressed with JN lately. He is kind of all over the place lately and got caught BSing this one on Twitter. If there is a big dump due to this offering I will take a look. BS? Like contradiction in thought process towards it? Would be curious to see his comments. My reason behind the investment wasn't solely based on him obviously but his article on it was what peaked me to do DD. Thanks!
|
|
|
Post by JHam on Jun 19, 2015 6:56:03 GMT
Yeah I have seen them. I have not been too impressed with JN lately. He is kind of all over the place lately and got caught BSing this one on Twitter. If there is a big dump due to this offering I will take a look. BS? Like contradiction in thought process towards it? Would be curious to see his comments. My reason behind the investment wasn't solely based on him obviously but his article on it was what peaked me to do DD. Thanks! Just about JN referring to this as an IPO which it isn't, but helps to hype his "promotion" of this stock. Then after being called on it, changing his tune. Also the he went from being bullish on NRIFF to suddenly being bearish on Twitter, to turning right around and being extremely bullish and writing his SA article. All within the span of a week or two.
|
|
madamemagoo
Junior Member
don't shoot mandy magoo!
Posts: 70
|
Post by madamemagoo on Jun 19, 2015 13:03:21 GMT
Did nicely yesterday - CTH.TO did even better.
|
|
|
Post by Yelk on Jun 20, 2015 16:22:58 GMT
|
|
|
Post by actcfan on Jun 23, 2015 16:33:19 GMT
I know nothing about this company, but $63M raised, 4.5M shares at $14 with no warrants. Plus they up-list to the Nasdaq tomorrow. Gotta like that. Good luck! Company is new to me but starting to take a look. Anyone who has been following know why they raised money in March and then again less than 3 months later? Thanks Sounds like P3 data and NDA expected in 2016, should be interesting.
|
|